CD8A and neoplasm: In 1 patient, who had excellent durable local response at the injected site (−79% from baseline at 456 days), there was a marked increase in the CD4+ T-cell infiltration into the tumor after injection (11%-34% of all stained cells) concomitant with an increase in the CD8+ T-cell fraction (0.3%-3.4%).